EGFR and non-small cell lung carcinoma: As an illustration, for NSCLC with epidermal growth factor receptors (EGFR) mutations, gefinitib and erlotinib have been reported to be as effective among older patients as in younger patients with less side effects compared to conventional chemotherapy [51].